IRadimed Forecasts FY24 Revenue of $72M-$74M, With Adjusted EPS Of $1.52-$1.62 Compared To Consensus Of $71.50M And $1.48, Respectively
Portfolio Pulse from Benzinga Newsdesk
IRadimed has projected its FY24 revenue to be between $72M-$74M and its adjusted EPS to be in the range of $1.52-$1.62, surpassing the consensus estimates of $71.50M in revenue and $1.48 in adjusted EPS.
February 08, 2024 | 1:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IRadimed's FY24 revenue and adjusted EPS forecasts exceed consensus estimates, indicating a positive outlook for the company's financial performance.
IRadimed's projection of higher-than-expected revenue and EPS for FY24 suggests strong business performance and operational efficiency. This positive outlook is likely to instill confidence among investors, potentially leading to an uptick in IRMD's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100